LOS ANGELES--(BUSINESS WIRE)--Dec. 12, 2005--Cougar Biotechnology, Inc, a privately held biotechnology company, today announced positive interim data from an ongoing Phase I trial of the Company’s drug CB3304 (noscapine), an orally active alkaloid that has been shown to induce conformational changes in tubulin, in patients with relapsed or refractory non-Hodgkin’s lymphoma. The data was presented as a poster presentation at the American Society of Hematology Annual Meeting in Atlanta, Georgia.
